Triplet Therapy, Transplantation, and Maintenance until Progression in MyelomaPaul G. Richardson, Irene M. Ghobrial, Edward N. Libby et al.|New England Journal of Medicine|2022Cited by 457
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapyGuido Ghilardi, Marco Ruella, Joseph A. Fraietta et al.|Nature Medicine|2024Cited by 254
Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I StudySuzanne Trudel, Simon J. Harrison, Adam D. Cohen et al.|Blood|2021Cited by 161
Paraproteinemic neuropathiesRebecca Traub, Chafic Karam, Taha Qarni et al.|Muscle & Nerve|2024Cited by 8